Provided by Tiger Trade Technology Pte. Ltd.

AC Immune SA

2.90
+0.26009.85%
Post-market: 2.83-0.0699-2.41%19:30 EDT
Volume:442.01K
Turnover:1.26M
Market Cap:295.14M
PE:-5.51
High:2.95
Open:2.66
Low:2.65
Close:2.64
52wk High:4.00
52wk Low:2.03
Shares:101.77M
Float Shares:39.19M
Volume Ratio:2.61
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5264
EPS(LYR):-0.8828
ROE:-78.53%
ROA:-16.04%
PB:6.73
PE(LYR):-3.29

Loading ...

Promising Penny Stocks To Consider In August 2026

Simply Wall St.
·
Yesterday

AC Immune Price Target Maintained with a $8.00/Share by BTIG

Dow Jones
·
Aug 20

AC Immune Reports Positive Interim Phase 1 Data for NLRP3 Inhibitor ACI-19764

Reuters
·
Aug 20

AC Immune Announces Positive Preliminary Phase 1 Data for Nlrp3 Inhibitor ACI-19764

THOMSON REUTERS
·
Aug 20

AC Immune - Full Phase 1/1B Results for ACI-19764 Expected in H1 2027

THOMSON REUTERS
·
Aug 20

AC Immune - ACI-19764 Safe and Well Tolerated with Confirmed Csf Penetration in Phase 1

THOMSON REUTERS
·
Aug 20

AC Immune - Based on Pk Data Therapeutic Dose is Expected to be ≤10Mg Once Daily

THOMSON REUTERS
·
Aug 20

AC Immune - no Serious Adverse Events or Treatment Withdrawals Reported for ACI-19764

THOMSON REUTERS
·
Aug 20

U.S. Stocks on the MOVEX-Abbott, Columbia Financial, Jabil,

Reuters
·
Aug 11

U.S. Stocks on the MOVE-Duke Energy, Sea, Cardinal Health

Reuters
·
Aug 11

AC Immune - Full Week-100 Results from Part 1 VacSYn Trial Expected in H2 2026

Reuters
·
Aug 11

AC Immune receives fast track designation, clearance for ACI-7104 IND

TIPRANKS
·
Aug 11

AC Immune Jumps After US FDA Grants Fast-Track Status for Parkinson's Disease Drug

Reuters
·
Aug 11

AC Immune - Interim Results Show Safety and Immunogenicity with Early Signals of Activity for ACI-7104

THOMSON REUTERS
·
Aug 11

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-Synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (Pd)

THOMSON REUTERS
·
Aug 11

AC Immune - Full Week-100 Results from Part 1 Vacsyn Trial Expected in H2 2026

THOMSON REUTERS
·
Aug 11

AC Immune Price Target Maintained with a $8.00/Share by BTIG

Dow Jones
·
Aug 06

AC Immune SA Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Ac Immune First Half 2026 Financial and Corporate Update

Reuters
·
Aug 05

AC Immune IFRS Net Loss Narrows to CHF 12.93 Million in H1 FY26; Revenue Rises to CHF 16.23 Million

Reuters
·
Aug 05